Trilogy of drug repurposing for developing cancer and chemotherapy-induced heart failure co-therapy agent.

"Conflicts of interest The authors declare no conflict of interest."

"This work was supported by the 10.13039/100014717National Natural Science Foundation of China (Grant Nos. 22177076, 81820108022, 22037002), the Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism (2021 Sci & Tech 03-28, China), Shanghai Frontiers Science Center of Disease and Syndrome Biology of Inflammatory Cancer Transformation (2021KJ03-12, China), the Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZDCX20212702, China), and the Chinese Special Fund for 10.13039/501100011513State Key Laboratory of Bioreactor Engineering (2060204), 10.13039/501100003395Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-10-E00056, 2021-01-07-00-02-E00104, China), the Scientific and Technological Innovation Action Plan of Science and Technology Commission of Shanghai (20JC1411300, China). We are also grateful for the help of Prof. Jin Huang, Prof. Yi Sun, Dr. Qing Yu, and Dr. Zhiguo Hu."